Meet our Supporters
MTIS would like to thank our supporters who are sponsoring and/or exhibiting at this year’s conference. Take a look at the companies below who you can meet in-person in September.
AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at abbvie.co.uk. Follow @abbvieuk on X, formerly known as Twitter, and YouTube (@abbvieuk6755)
UK-ABBV-230374 / September 2023
The British Association for the Study of Headache (BASH)
The British Association for the Study of Headache (BASH) is the United Kingdom national society member of the European Headache Federation (EHF).
Membership is open to all healthcare professionals with an interest in headache. We work closely with other UK and international headache groups.
The Association was founded in 1992 by Dr TJ Steiner, The Princess Margaret Migraine Clinic, Charing Cross Hospital, London and was incorporated in 1998.
As in all limited companies, the management of BASH is in the hands of a Board of Directors, which is known as Council. The members of Council are also the Trustees of the Charity, and have responsibility for the day-to-day running of the Association. “
Dr Reddys
As a multinational pharmaceutical company, we are guided by our purpose to accelerate access to affordable and innovative medicines, because we believe that “Good Health Can’t Wait”. This credo unites over 24000 employees worldwide. We aspire to provide a culture of empathy and dynamism that allows us to understand the needs of our patients and partners. Today millions of patients in over 66 countries have access to Dr. Reddy’s products.
Our goal is always to ensure Good Health. For us, drugs are not just molecules, but tools that help patients heal. Can’t wait reflects our commitment to act quickly to find innovative solutions that address patients’ unmet needs and accelerate access to much-needed medicines for people around the world.
Since our establishment in 2002, we have supported UK’s healthcare system with our affordable prescription and OTC medicines portfolio. Our presence in the UK includes commercial offices in Cambridge, an R&D center in Cambridge, and an Active Pharmaceutical Ingredient (API) manufacturing site in Mirfield.
European Headache Congress
Dear colleagues,
The world is dynamic like never before. While there are many positive developments regarding novel treatments against headache, unfortunately there is still a lot of inequity in the world regarding access to these treatments, but also regarding the effectiveness across different populations. The European Headache Federation strives to improve health and promote well-being for all individuals with headache. To achieve that goal, it is crucial to connect fundamental scientific knowledge with a clinical perspective, as will be offered in our congress programme.
We therefore look forward to welcoming you to the 18th European Headache Congress held in Rotterdam from 4 to 7 December 2024.
Towards a better headache treatment for everyone.
Prof. Antoinette Maassen van den Brink and Prof. Jan Versijpt
Congress chairs
Electrocore
In 2005, we were founded on a unified belief that neuromodulation could be used in novel ways to help patients break free from treatments they aren’t happy with. Because different modalities of neuromodulation had previously proven to be effective and safe, we recognized an opportunity to be the leader in this new frontier of medicine and embraced it.
Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients’ treatment options and lives.
We are committed to behaving in a fair, honest, and transparent manner that enables long-term, positive relationships to be built on solid foundations of trust and credibility. We are driven by a strong sense of responsibility to advance the availability of our product to the patients who need it.
We also recognize the role of all stakeholders in the success of the organization and welcome and respect their input and opinions.
The European Migraine and Headache Alliance (EMHA)
The European Migraine and Headache Alliance is a non-profit patient association, which functions as an umbrella organisation for different patient groups across Europe. The Alliance was establi- shed in 2006 and since then we represent more than 30 patient groups across the continent. Also, we work closely with International Associates in Canada, US, Turkey, Argentina, Brazil, Mexico, Philippi- nes and Chile.
Our Goal: Fighting migraine.
Although migraine is one of the most common diseases, it is, at the same time, one of the most unknown and ignored, both by the healthcare system, politicians, companies and society in general.
At EMHA, we try to raise awareness in all these areas with the goal of normalising the disease and eradicating the stigma that patients have to endure. This is why the Migraine Friendly Workplace project focuses all efforts on improving the lives of millions of European workers who, even nowadays, have to work in an environment that does not understand them and, therefore, does not help them.
International Headache Society (IHS)
The International Headache Society (IHS) is the world’s leading membership organisation for all whose professional commitment, whatever their discipline, is to helping people whose lives are affected by headache.
Activities include publication of the open access scientific journals, Cephalalgia and Cephalalgia Reports), the bi-ennial International Headache Congress (IHC – next congress São Paulo, Brazil, September 2025), developing guidelines, including the International Classification of Headache Disorders (ICHD), educating the next generation of headache specialists worldwide, taking headache educators to areas of the world which might need or want increased headache education and motivation and where, without financial support, attendance of an international specialist would not be possible, online education materials, and offering grants and fellowships to young physicians worldwide.
IHS members are medical and healthcare practitioners (including such practitioners actively involved in scientific research) who are professionally engaged or involved in the study of headache disorders. National headache societies join IHS as Affiliate Member Societies. Associate Membership, enabling free of charge membership, is available without payment of a fee to those who qualify for membership of the Society and are residents of lower-income countries.
For more information on IHS and its activities please visit the IHS website.
Cephalalgia is the official journal of IHS. The journal contains original papers on all aspects of headache and provides an international forum for original research papers, review articles and short communications.
IHS members enjoy reduced publication fees for Cephalalgia and Cephalalgia Reports and direct access to the full back catalogue of Cephalgia.
Please visit the Cephalalgia website for more information.
Lundbeck
Lundbeck is a global pharmaceutical company specialising in brain diseases.
We are tirelessly dedicated to restoring brain health, so every person can be their best. To fulfill this purpose, Lundbeck engages in the research, development, manufacturing, and commercialisation of pharmaceuticals across the world. For more than 70 years, Lundbeck has been at the forefront of neuroscience research.
UK-VYEP-0518 Date or preparation: Aug, 2024
Migraine Trust
The Migraine Trust is the UK’s leading migraine charity providing information and support, campaigning for awareness and change, and funding and promoting research.
One in seven people in the UK live with migraine, and this complex and debilitating neurological disorder significantly affects their lives. We have been leading and bringing the migraine community together to change this since 1965. Every year over two million people visit our website, and thousands contact our helplines for information and support on all aspects of migraine, including help in managing it at work, in education, and in accessing healthcare. We campaign for increased awareness and understanding of migraine, and national policy change to improve the lives of people who get it. We have funded over 140 medical research projects and hold this conference every two years – we look forward to welcoming you to the Migraine Trust International Symposium!
Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Organon
Organon is an independent global healthcare company with a strategy to help improve the health of women throughout their lives. Organon’s diverse portfolio offers more than 60 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth prospects in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialise their products by leveraging its scale and agile presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, six manufacturing sites worldwide and approximately 10,500 employees.
Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS. To learn more about our commitments, please visit us at www.pfizer.co.uk or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).
PP-NNT-GBR-0848 September 2023
TEVA
As the global leader in generic medicine, nearly 200 million people across six continents take one of our products every day. We also invest hundreds of millions of dollars every year to help our scientists develop specialty and biopharmaceutical treatments that aim to increase access and improve patients’ health. Since Teva’s establishment in 1901 in Jerusalem, our leadership in healthcare has been marked by tenacity, entrepreneurial spirit, and an aspiration to improve people’s lives. This defines how we do business and motivates thousands of Teva employees all over the world, every single day.
Migraine Trust International Symposium
c/o Conference Collective Ltd
8 Waldegrave Road
Teddington
Middlesex
TW11 8GT
United Kingdom